Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
STAMFORD, Conn., Nov. 22, 2016 -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced that Dr. Derek Chalmers, President and CEO, will participate in a fireside chat at the 28th Annual Piper Jaffray Healthcare Conference on Tuesday, November 29, 2016, at 4:30 p.m. ET in New York City.
A live webcast of the presentation can be accessed under “Events and Presentations” in the News & Investors section of the Company’s website at www.CaraTherapeutics.com. An archived webcast recording will be available on the Cara website for approximately 30 days.
About Cara Therapeutics
Cara Therapeutics is a clinical-stage biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors. Cara is developing a novel and proprietary class of product candidates that target the body's peripheral nervous system and have demonstrated initial efficacy in patients with moderate-to-severe pain without inducing many of the undesirable side effects typically associated with currently available pain therapeutics.
INVESTOR CONTACT: Michael Schaffzin Stern Investor Relations, Inc. 212-362-1200 [email protected] MEDIA CONTACT: Annie Starr 6 Degrees 973-415-8838 [email protected]
